- Home
- ACAD vs BHC Comparison
ACAD vs BHC Comparison
Compare ACAD & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- BHC
- Stock Information
- Founded
- ACAD 1993
- BHC N/A
- Country
- ACAD United States
- BHC Canada
- Employees
- ACAD N/A
- BHC N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- BHC Biotechnology: Pharmaceutical Preparations
- Sector
- ACAD Health Care
- BHC Health Care
- Exchange
- ACAD Nasdaq
- BHC Nasdaq
- Market Cap
- ACAD 2.8B
- BHC 2.6B
- IPO Year
- ACAD 2004
- BHC N/A
- Fundamental
- Price
- ACAD $14.73
- BHC $5.10
- Analyst Decision
- ACAD Buy
- BHC Hold
- Analyst Count
- ACAD 16
- BHC 5
- Target Price
- ACAD $23.93
- BHC $7.20
- AVG Volume (30 Days)
- ACAD 1.8M
- BHC 3.0M
- Earning Date
- ACAD 05-07-2025
- BHC 04-30-2025
- Dividend Yield
- ACAD N/A
- BHC N/A
- EPS Growth
- ACAD N/A
- BHC N/A
- EPS
- ACAD 1.36
- BHC N/A
- Revenue
- ACAD $957,797,000.00
- BHC $9,625,000,000.00
- Revenue This Year
- ACAD $13.07
- BHC $4.76
- Revenue Next Year
- ACAD $9.88
- BHC $2.05
- P/E Ratio
- ACAD $10.83
- BHC N/A
- Revenue Growth
- ACAD 31.85
- BHC 9.91
- 52 Week Low
- ACAD $13.40
- BHC $3.96
- 52 Week High
- ACAD $20.68
- BHC $9.85
- Technical
- Relative Strength Index (RSI)
- ACAD 38.07
- BHC 39.07
- Support Level
- ACAD $14.34
- BHC $4.28
- Resistance Level
- ACAD $15.18
- BHC $5.45
- Average True Range (ATR)
- ACAD 0.80
- BHC 0.41
- MACD
- ACAD -0.02
- BHC -0.06
- Stochastic Oscillator
- ACAD 38.22
- BHC 37.44
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.